Sharing-our-perspective-page-header2



Sharing perspectives leads to greater understanding and fuels innovation. The ​Optum Insights ​blog is where we share our perspective and challenge preconceptions to clear a new path forward


  • FDA approves Vosevi™ for the treatment of chronic Hepatitis C virus infection

    by
    • Optum Workers' Comp
    | Jul 20, 2017
    Tag Icon
    Workers Comp, Medication Plans, FDA
    The U.S. Food and Drug Administration (FDA) has approved a new fixed-dose, combination medication Vosevi™ to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis.


  • California Releases Revised Drug Formulary Rule

    by
    • Optum Workers' Comp
    | Jul 19, 2017
    Tag Icon
    Workers Comp, CA DWC, Formularies
    The California DWC released its revised drug formulary rule and opened a 15-day comment period expiring August 2, 2017. The rule contains some pertinent changes, summarized here.


  • CMS Expands Re-review Process

    by
    • Optum Workers' Comp
    | Jul 13, 2017
    Tag Icon
    Workers Comp, MSA, Medicare Set-Aside, CMS
    The long awaited update to the Workers’ Compensation Medicare Set-Aside (WCMSA) Re-Review process, as promised by The Centers for Medicare and Medicaid Services (CMS) in late December 2016, has arrived.


  • Opioid analgesics have a place in therapy; knowing when and how to use is key

    by
    • Optum Workers' Comp
    | Jul 11, 2017
    Tag Icon
    Workers Comp, Pain Management, Opioids, FDA, Chronic Pain
    The recent agreement between the U.S. Food and Drug Administration (FDA) and Endo Pharmaceuticals to have Opana® ER removed from the U.S. market highlights the ongoing need for awareness on the safety of opioid analgesics and a better understanding of how the medication can affect the major body systems. While this decision resulted from research determining the benefits of using reformulated Opana ER no longer outweigh its risks, the question of whether or not opioid analgesics should continue to have a place in medication therapy remains.


  • Kentucky takes stance on gabapentin to help reduce risk to public health

    by
    • Optum Workers' Comp
    | Jul 07, 2017
    Tag Icon
    Workers Comp, FDA, DEA, Abuse Deterrent
    Kentucky has recently classified all gabapentin products as a Schedule V Controlled Substance to help reduce the risk to public health. This new state regulation, effective July 1, 2017, differs from federal regulations in that the state of Kentucky recognizes the abuse potential of gabapentin.


  • Endo has provided an update to the FDA

    by
    • Optum Workers' Comp
    | Jul 06, 2017
    Tag Icon
    Workers Comp, Medication Recall, FDA
    UPDATE: Endo International plc has released a statement regarding the U.S. Food and Drug Administration’s (FDA) request in June 2017, to remove its reformulated Opana® ER (oxymorphone hydrochloride extended-release) from the market.


  • Louisiana Supreme Court settles pharmacy choice issue, employers retain the right to choose

    by
    • Optum Workers Comp
    | Jul 05, 2017
    Tag Icon
    Workers' Compensation
    Since the initiation of Sigler v. Rand in 2004, the Louisiana courts have been wrestling with the issue of who has the right to choose a pharmacy for an injured worker: the employer or the injured worker themselves. At the heart of the issue is Louisiana RS23:1203 which states, “the employer shall furnish all necessary drugs…” The lower courts in Louisiana have been split on whether or not this language in the statute grants authority to the employer to choose the pharmacy or if the employee is allowed to choose.



Stay informed by receiving latest updates

Do you have a question about a blog post?